【摘要】 目的:了解吉西他滨(健择)联合顺铂治疗晚期肝癌的疗效与不良反应。方法:采用吉西他滨(健择)联合顺铂治疗40例晚期肝癌患者。吉西他滨(健择)1 000~1 250m g/m2,平均使用剂量1 115m g/m2,静脉滴注30m in,第1,8天,顺铂25m g/m2,静脉滴注,第1~3天,21d为1周期,至少完成2周期疗效评价。结果:40例患者中无CR患者,PR 11例占27.5%,NC 25例占62.5%,PD 4例占10.0%,总有效率27.5%。中位生存时间为7.2个月,1年生存率为45.8%。主要不良反应为血液毒性,骨髓抑制发生率中白细胞减少占周期数的61%,血红蛋白减少占20%,血小板减少占29%。其余不良反应轻微。结论:吉西他滨联合顺铂治疗晚期肝癌疗效好,不良反应可耐受,可提高患者的生存质量。更多还原

【Abstract】 Objective: To study the efficacy and side reactions of gemcitabine combined with cisplatin in the treatment of advanced liver cancer.Methods: 40 patients with advanced liver cancer were involved in this study.Gemcitabine was used intravenously by infusion for 30 min with the dose from 1000 mg/m~2 to 1250 mg/m~2 on day 1,8;cisplatin was infused intravenously with a dose of 25mg/m~2 on day1~3.Twenty-one days were counted as one cycle.After 2 cycles chemotherapy completed,the efficacy,side reaction and clinical symptoms were evaluated.Results: In these 40 patients,no patients was evaluated as completed response,11 cases(27.5%) were PR,25 cases(62.5%)were NC,2 cases(10.0%) were PD. The mean survival time for all 40 patients was 7.2 month and the 1-year survival rate was 45.8%.Hematologic toxicity was the main side reaction,which included leucopenia(61.0%),anemia(20.0%),thrombocytopenia(29.0%),and the other adverse reactions were little.Conclusions: Gemcitabine combined with cisplatin is an effective regimen for advanced liver cancer.Its side reactions are tolerable.更多还原